Amlod/atorva
Pro Research Analysisby 
Searched over 200M research papers for "amlod/atorva"
Efficacy and Safety of Amlodipine/Atorvastatin Combination Therapy
Introduction to Amlodipine/Atorvastatin Combination Therapy
Amlodipine/atorvastatin (Caduet®) is a single-tablet, fixed-dose combination of the calcium channel blocker amlodipine and the HMG-CoA reductase inhibitor atorvastatin. This combination targets two major cardiovascular risk factors: hypertension and dyslipidemia. The bioavailability of both drugs in the combination tablet is comparable to their separate administration, making it a convenient option for patients.
Blood Pressure and Lipid Control
Efficacy in Achieving Blood Pressure and Lipid Goals
Clinical trials have demonstrated that the combination of amlodipine and atorvastatin is effective in reducing both systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) levels. In the TOGETHER trial, 67.8% of participants receiving the combination therapy achieved both BP and LDL-C goals, compared to only 9.6% with amlodipine alone. Similarly, the CRUCIAL trial showed a significant reduction in the calculated Framingham 10-year coronary heart disease (CHD) risk with the combination therapy compared to usual care.
Improved Vascular Function
The combination therapy has also been shown to improve vascular function. A study comparing amlodipine alone to the combination therapy found that the latter significantly improved flow-mediated dilation (FMD) and reduced central arterial blood pressure. Another study indicated that the combination therapy was more effective in reversing left ventricular hypertrophy and reducing interstitial fibrosis in hypertensive rats.
Cardiovascular Risk Reduction
Prevention of Cardiovascular Events
The ASCOT-LLA trial demonstrated that the combination of amlodipine-based therapy and atorvastatin was effective in preventing cardiovascular (CV) endpoints in hypertensive patients at risk of cardiovascular disease (CVD). This multifactorial approach to CV risk management is more effective than targeting individual risk factors separately.
Inflammatory Cytokine Regulation
Research has shown that the combination therapy can inhibit inflammatory cytokine networks, such as TNF-α, IL-1β, and NF-κB, which are involved in ventricular hypertrophy and diastolic dysfunction. This suggests that the combination therapy may have additional benefits in reducing inflammation-related cardiovascular damage.
Patient Adherence and Safety
Improved Adherence
The single-tablet combination of amlodipine/atorvastatin has been shown to improve patient adherence compared to the coadministration of separate tablets. A retrospective study using prescription refill rates from a large US insurance database confirmed this finding.
Safety Profile
The combination therapy is generally well-tolerated. Common adverse events include peripheral edema, headache, and myalgia, but these are consistent with the known safety profiles of the individual drugs. The Respond trial confirmed that there were no adverse pharmacodynamic interactions between the two drugs, ensuring the safety of the combination therapy.
Conclusion
Amlodipine/atorvastatin combination therapy offers a convenient and effective approach to managing hypertension and dyslipidemia, thereby reducing cardiovascular risk. It improves patient adherence, achieves better control of BP and LDL-C levels, and has a favorable safety profile. This makes it a valuable option for patients with multiple cardiovascular risk factors.
Sources and full results
Most relevant research papers on this topic